23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Beta-Catenin Causes Adrenal Hyperplasia by Blocking Zonal Transdifferentiation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Activating mutations in the canonical Wnt/β-catenin pathway are key drivers of hyperplasia, the gateway for tumor development. In a wide range of tissues, this occurs primarily through enhanced effects on cellular proliferation. Whether additional mechanisms contribute to β-catenin-driven hyperplasia remains unknown. The adrenal cortex is an ideal system in which to explore this question, as it undergoes hyperplasia following somatic β-catenin gain-of-function (βcat-GOF) mutations. Targeting βcat-GOF to zona Glomerulosa (zG) cells leads to a progressive hyperplastic expansion in the absence of increased proliferation. Instead, we find that hyperplasia results from a functional block in the ability of zG cells to transdifferentiate into zona Fasciculata (zF) cells. Mechanistically, zG cells demonstrate an upregulation of Pde2a, an inhibitor of zF-specific cAMP/PKA signaling. Hyperplasia is further exacerbated by trophic factor stimulation leading to organomegaly. Together, these data indicate that β-catenin drives adrenal hyperplasia through both proliferation-dependent and -independent mechanisms.

          Graphical Abstract

          In Brief

          Using the adrenal cortex as a model for slow-cycling tissues, Pignatti et al. show that activation of the canonical Wnt/β-catenin pathway leads to tissue hyperplasia by blocking cellular differentiation/cell-fate commitment, independent of its effects on cellular proliferation.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Wnt/β-Catenin/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of the Signaling Pathway

          Axin2/Conductin/Axil and its ortholog Axin are negative regulators of the Wnt signaling pathway, which promote the phosphorylation and degradation of β-catenin. While Axin is expressed ubiquitously, Axin2 mRNA was seen in a restricted pattern during mouse embryogenesis and organogenesis. Because many sites of Axin2 expression overlapped with those of several Wnt genes, we tested whether Axin2 was induced by Wnt signaling. Endogenous Axin2 mRNA and protein expression could be rapidly induced by activation of the Wnt pathway, and Axin2 reporter constructs, containing a 5.6-kb DNA fragment including the promoter and first intron, were also induced. This genomic region contains eight Tcf/LEF consensus binding sites, five of which are located within longer, highly conserved noncoding sequences. The mutation or deletion of these Tcf/LEF sites greatly diminished induction by β-catenin, and mutation of the Tcf/LEF site T2 abolished protein binding in an electrophoretic mobility shift assay. These results strongly suggest that Axin2 is a direct target of the Wnt pathway, mediated through Tcf/LEF factors. The 5.6-kb genomic sequence was sufficient to direct the tissue-specific expression of d2EGFP in transgenic embryos, consistent with a role for the Tcf/LEF sites and surrounding conserved sequences in the in vivo expression pattern of Axin2 . Our results suggest that Axin2 participates in a negative feedback loop, which could serve to limit the duration or intensity of a Wnt-initiated signal.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Wnt signaling in cancer.

            Aberrant regulation of the Wnt signaling pathway is a prevalent theme in cancer biology. From the earliest observation that Wnt overexpression could lead to malignant transformation of mouse mammary tissue to the most recent genetic discoveries gleaned from tumor genome sequencing, the Wnt pathway continues to evolve as a central mechanism in cancer biology. This article summarizes the evidence supporting a role for Wnt signaling in human cancer. This includes a review of the genetic mutations affecting Wnt pathway components, as well as some of epigenetic mechanisms that alter expression of genes relevant to Wnt. I also highlight some research on the cooperativity of Wnt with other signaling pathways in cancer. Finally, some emphasis is placed on laboratory research that provides a proof of concept for the therapeutic inhibition of Wnt signaling in cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integrated genomic characterization of adrenocortical carcinoma.

              Adrenocortical carcinomas (ACCs) are aggressive cancers originating in the cortex of the adrenal gland. Despite overall poor prognosis, ACC outcome is heterogeneous. We performed exome sequencing and SNP array analysis of 45 ACCs and identified recurrent alterations in known driver genes (CTNNB1, TP53, CDKN2A, RB1 and MEN1) and in genes not previously reported in ACC (ZNRF3, DAXX, TERT and MED12), which we validated in an independent cohort of 77 ACCs. ZNRF3, encoding a cell surface E3 ubiquitin ligase, was the most frequently altered gene (21%) and is a potential new tumor suppressor gene related to the β-catenin pathway. Our integrated genomic analyses further identified two distinct molecular subgroups with opposite outcome. The C1A group of ACCs with poor outcome displayed numerous mutations and DNA methylation alterations, whereas the C1B group of ACCs with good prognosis displayed specific deregulation of two microRNA clusters. Thus, aggressive and indolent ACCs correspond to two distinct molecular entities driven by different oncogenic alterations.
                Bookmark

                Author and article information

                Journal
                101573691
                39703
                Cell Rep
                Cell Rep
                Cell reports
                2211-1247
                1 May 2020
                21 April 2020
                09 June 2020
                : 31
                : 3
                : 107524
                Affiliations
                [1 ]Division of Endocrinology, Boston Children’s Hospital, Boston, MA 02115, USA
                [2 ]Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
                [3 ]Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA
                [4 ]Department of Pharmacology, University of Virginia, Charlottesville, VA 22947, USA
                [5 ]Division of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto 606-8506, Japan
                [6 ]Harvard Stem Cell Institute, Cambridge, MA 02138, USA
                [7 ]These authors contributed equally
                [8 ]Lead Contact
                Author notes

                AUTHOR CONTRIBUTIONS

                E.P., S.L. D.L.C., and D.T.B. conceptualized the study; E.P., S.L., and D.T.B. developed the methodology; E.P., S.L., Y.Y., M.S.S., G.R.-B., N.A.G., K.S.B., J.M., D.K., D.L.C., and D.T.B. designed experiments; E.P., S.L., and Y.Y. performed experiments; M.M.T. provided essential material and advice; E.P., S.L., D.L.C., and D.T.B. wrote the original manuscript with editorial inputs from all authors; D.L.C., P.Q.B., and D.T.B. provided supervision; and D.T.B. acquired funds.

                Article
                NIHMS1586763
                10.1016/j.celrep.2020.107524
                7281829
                32320669
                b5106646-7162-4371-ab8f-2b750a250d78

                This is an open access article under the CC BY-NC-ND license.

                History
                Categories
                Article

                Cell biology
                Cell biology

                Comments

                Comment on this article